tradingkey.logo
tradingkey.logo
Search

Scholar Rock Holding Corp

SRRK
Add to Watchlist
47.330USD
+0.380+0.81%
Close 06/18, 16:00ETQuotes delayed by 15 min
5.13BMarket Cap
LossP/E TTM

Earnings Forecast

Currency: USD Updated: 2026-06-18
Previous score
8.78
Change
0
The current earnings forecast score of Scholar Rock Holding Corp is 8.78, ranking 62 out of 389 in the Biotechnology & Medical Research industry. The average price target is 47.50, with a high of 53.00 and a low of 42.00.

Analyst Rating

Based on 18 analysts
Buy
Current Rating
59.533
Target Price
+25.78%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

560
Total
5
Median
6
Average
Company name
Ratings
Analysts
Scholar Rock Holding Corp
SRRK
18
Beigene Ltd
ONC
27
CRISPR Therapeutics AG
CRSP
27
Ionis Pharmaceuticals Inc
IONS
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
1
2
3
...
112

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS
Revenue
Net Profit
EBIT
Forecast
Actual

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

FAQs

What is Scholar Rock Holding Corp's expected revenue for the next quarter?

Scholar Rock Holding Corp's expected revenue is 50.00K.

What is Scholar Rock Holding Corp's price target?

Analysts forecast that Scholar Rock Holding Corp's price target is USD 47.50, with the highest forecast at USD 53.00 and the lowest forecast at USD 42.00.

How have Scholar Rock Holding CorpSRRK's recent earnings per share performed?

The market expectation was USD -0.82, while Scholar Rock Holding CorpSRRK's earnings per share (EPS) for the previous quarter was USD -0.75. EPS for the next quarter is expected at USD -0.84.

What is the analyst rating for Scholar Rock Holding Corp?

Based on the ratings of Scholar Rock Holding Corp's stock from 18 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
KeyAI